Regis Healthcare names Andrew Kinkade as new CEO

Regis Healthcare appoints Andrew Kinkade as CEO, unveiling new leadership strategy and key remuneration details.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Regis Healthcare Ltd (ASX: REG) share price is in focus today after the company announced the appointment of Andrew Kinkade as its new Managing Director and Chief Executive Officer. Kinkade joins Regis with an extensive leadership background in aged care, healthcare and finance.

CEO of a company talking.

Image source: Getty Images

What did Regis Healthcare report?

  • Appointment of Andrew Kinkade as new Managing Director & CEO, commencing 20 July 2026
  • Total fixed remuneration of $900,000 per annum, inclusive of superannuation
  • Short Term Incentive of up to 50% of TFR and Long Term Incentive of up to 100% of TFR, subject to performance
  • Sign-on equity award of $1.6 million in Performance Rights, subject to shareholder approval

What else do investors need to know?

Andrew Kinkade brings more than 20 years of experience across aged care, healthcare, private equity, and investment banking, most recently serving as Managing Director at Bupa Villages & Aged Care. He has been recognised for leading operational and cultural transformation, driving both growth and improved care standards.

Kinkade replaces Dr Linda Mellors, who will complete her notice period in June after leading the company for over six years. The board expressed its appreciation for Dr Mellors' significant contributions and steady leadership throughout her tenure.

What's next for Regis Healthcare?

Kinkade's appointment signals a focus on operational transformation and strengthening Regis's position in Australia's aged care sector. The Board noted his track record of leading growth in regulated, people-focused businesses, which aligns with Regis Healthcare's strategic objectives.

Shareholders will vote on key elements of Kinkade's remuneration package, including his sign-on equity award, at the upcoming Annual General Meeting. The company expects a smooth transition and ongoing delivery on its growth plans.

Regis Healthcare share price snapshot

Over the past 12 months, Regis Healthcare shares have declined 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 300 share crashing over 20% today?

It is a very red day for this healthcare stock. What's happening? Let's find out.

Read more »

Six smiling health workers pose for a selfie.
Broker Notes

3 reasons this beaten down ASX All Ords healthcare share could come roaring back

A leading analyst believes this beaten down ASX healthcare stock is well-positioned for a comeback.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Healthcare Shares

Down 59%: Will CSL shares ever regain momentum?

Here's what to expect over the next 12 months.

Read more »

A woman sits in front of a computer and does some calculations.
Healthcare Shares

Should you buy ResMed shares at their 52-week low?

This company is still growing, profitable, and exposed to a large sleep health market, but the share price has fallen…

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Healthcare Shares

How low can CSL shares go?

CSL shares have fallen 44% this year. Can they fall further?

Read more »

woman in lab coat conducting testing.
Healthcare Shares

3 reasons why this ASX biotech stock could double in value

Growing revenue and broker optimism are boosting confidence.

Read more »

Devastated man with his head on his office desk with paperwork and a laptop.
Healthcare Shares

Down 63%: Should you finally give up on CSL shares?

Things keep going from bad to worse for this biotech giant.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Down 40% but not out: Is Pro Medicus the buy of the decade right now?

Pro Medicus posted strong financial results.

Read more »